Author: admin

Alan Korman PhD, Chairman

Dr. Korman is Senior Vice President of Human Immunology at Vir Biotechnology. Previously, he was Vice President for Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS), where he led the development of biologics for tumor immunotherapy. Prior to BMS, he held various positions at Medarex. His tenure at BMS and Medarex led to the development of two […]

Read More

Tehila Ben Moshe Ph.D., Co-Founder, Chairperson & Chief Executive Officer

Tehila is the Co-Founder of Biond. She has served as Biond’s CEO and Board of Directors chairperson since the company’s inception. Tehila brings over a decade of scientific excellence and entrepreneurial leadership in biotech and pharma, combined with proven leadership skills and business acumen. Prior to founding Biond, Tehila was the CEO of cCAM Biotherapeutics […]

Read More

Avidor Shulman Ph.D., VP R&D

Avidor has served as Biond’s VP R&D since its inception and has over 20 years of experience in applied R&D, including all aspects of product development, innovation management & entrepreneurship. Prior to Biond, Avidor was Senior Director of Protein Chemistry at Protalix Biotherapeutics (NASDAQ: PLX) where he established the Protein Chemistry department. Avidor and his […]

Read More

Ilana Mandel Ph.D., VP Discovery

Ilana has served as Biond’s VP Discovery since its inception and brings extensive knowledge and experience in immunology and innovative drug development. Prior to Biond, Ilana was Director of Research and Discovery at cCAM Biotherapeutics where she led the research of the company’s lead product from early stage up to clinical studies and managed several […]

Read More

Itay Friedman M.D., VP Clinical Development

Itay serves as Biond’s VP Clinical Development since 2018. He has over 15 years of diversified R&D and Commercial experience developing and delivering innovative medicines and medical technologies. Itay joined Biond from Bristol-Myer Squibb (BMS) where he was Medical Affairs lead for Oncology, Hemato-oncology, and Virology brands in addition to holding regional Business Development and […]

Read More

post-left

Developing the ability to deliver antibodies to disease-relevant cells will expose diverse previously-untouchable intra-cellular targets. This technology will potentially enhance the possibilities of successful treatments for cancer and other diseases. The use of antibodies to influence intra-cellular targets will enable benefiting from their superior affinity and specificity over small-molecule drugs which are currently the only […]

Read More